BiotechTube
Home/Immunome/Clay Siegall, Ph.D.
CS

Clay Siegall, Ph.D.

President & Chief Executive Officer

Immunome

Therapeutic Areas

Oncology

Immunome Pipeline

DrugIndicationPhase
Varegacestat (AL102)Progressing Desmoid TumorsPhase 3
IM-1021ROR1+ Solid TumorsPhase 1
IM-3050FAP+ Solid Tumors (Radioligand Therapy)IND Cleared
IM-1617Undisclosed Solid Tumor TargetPreclinical
IM-1340Undisclosed Solid Tumor TargetPreclinical
IM-1335Undisclosed Solid Tumor TargetPreclinical

Leadership Team at Immunome

JH
Jack Higgins, Ph.D.
Chief Scientific Officer
KH
Kinney Horn
Chief Business Officer
BL
Bob Lechleider, M.D.
Chief Medical Officer
MR
Max Rosett
Chief Financial Officer
RS
Roee Shahar
EVP, Commercial
View full Immunome profile